BioCentury
ARTICLE | Clinical News

Merck reports data from Januvia CVOT

June 10, 2015 1:51 AM UTC

Merck & Co. Inc. (NYSE:MRK) reported results from the TECOS cardiovascular outcomes trial (CVOT) of Januvia sitagliptin, which Merck had previously said met the study's primary endpoint of non-inferiority vs. placebo in time to first CV event. Data were presented at the American Diabetes Association meeting and published in the New England Journal of Medicine.

After a median follow-up of three years, CV events including CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke or hospitalization for unstable angina occurred in 11.4% of Januvia-treated patients vs. 11.6% on placebo in the intent-to-treat population (HR=0.98; 95% CI: 0.89, 1.08). The intent-to-treat analysis included 14,671 patients with Type II diabetes. ...